Home › NDC Lookup › RxCUI directory › RxCUI 810079

24 HR fesoterodine fumarate 8 MG Extended Release Oral Tablet [Toviaz] — RxCUI 810079

RxNorm drug concept · Semantic branded drug
RxCUI 810079 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI810079
Official name24 HR fesoterodine fumarate 8 MG Extended Release Oral Tablet [Toviaz]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as24 HR Toviaz 8 MG Extended Release Oral Tablet; Toviaz 8 MG 24HR Extended Release Oral Tablet
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)5,050 prescriptions · 16 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Fesoterodine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It's calming down overactive signals in your bladder muscle. When your bladder squeezes too often or too urgently, it's because certain nerve receptors are overstimulated. Fesotero...
  • What is fesoterodine actually doing for my bladder?
  • No, you can take it with or without food — it works either way. The one thing that does matter is how you take the tablet: swallow it whole with a glass of liquid. Don't chew, crus...
  • Dry mouth is the most common side effect, and it's more noticeable at higher doses. Sipping water throughout the day, chewing sugar-free gum, or using sugar-free hard candies can h...
📖 Read our full Fesoterodine guide →

🕸️ Concept Web — How 24 HR fesoterodine fumarate 8 MG Extended Releas... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 24 HR fesoterodine fumarate 8 MG Extended Release Oral Tablet [Toviaz] RxCUI 810079

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Fesoterodine 797195
    • Fesoterodine fumarate 797196
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Toviaz 810072
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Fesoterodine Extended Release Oral Tablet 810070
    • Fesoterodine fumarate Extended Release Oral Tablet 2645392
    • Fesoterodine Oral Product 1165004
    • Fesoterodine Pill 1165005
    • Fesoterodine fumarate Oral Product 2659430
    • Fesoterodine fumarate Pill 2661906
    • Fesoterodine Extended Release Oral Tablet [Toviaz] 810074
    • Fesoterodine fumarate Extended Release Oral Tablet [Toviaz] 2655513
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • 24 HR fesoterodine fumarate 8 MG Extended Release Oral Tablet SCD · 810077
  • Fesoterodine fumarate 8 MG SCDC · 810076
  • Fesoterodine Extended Release Oral Tablet SCDF · 810070
  • Fesoterodine fumarate Extended Release Oral Tablet SCDFP · 2645392
  • Fesoterodine Oral Product SCDG · 1165004
  • Fesoterodine Pill SCDG · 1165005
  • Fesoterodine fumarate Oral Product SCDGP · 2659430
  • Fesoterodine fumarate Pill SCDGP · 2661906

Brand-Name Concepts

  • Fesoterodine fumarate 8 MG [Toviaz] SBDC · 810078
  • Fesoterodine Extended Release Oral Tablet [Toviaz] SBDF · 810074
  • Fesoterodine fumarate Extended Release Oral Tablet [Toviaz] SBDFP · 2655513
  • Toviaz Oral Product SBDG · 1178619
  • Toviaz Pill SBDG · 1178620
  • Toviaz BN · 810072

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 810079 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00069-0242-30 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0069-0... Toviaz Pfizer Laboratories Div Pfizer Inc 2008-10-31
00069-0244-30 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0069-0... Toviaz Pfizer Laboratories Div Pfizer Inc 2008-10-31
Observed labelers: Pfizer Laboratories Div Pfizer Inc (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.